insights_auto
Outlook: 45.5% bullish·9.1% bearish
Go to analysischevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
229,26 $
arrow_downward
-1,47%(-3,42) 1D
12 қаз., 12:44:53 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
233,13 $
High
233,60 $
Low
228,49 $
Mkt. cap
30,68 млрд
Avg. vol.
1,49 млн
Volume
373,76 м.
P/E ratio
39,02
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 млн
No. of employees
2 мың
Open
233,13 $
High
233,60 $
Low
228,49 $
Mkt. cap
30,68 млрд
Avg. vol.
1,49 млн
Volume
373,76 м.
P/E ratio
39,02
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 млн
No. of employees
2 мың
News stories
From web sources and news partners
Investing.com
·
1 күн бұрын
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
1 күн бұрын
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
1 күн бұрын
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Yahoo Finance
·
2 күн бұрын
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.